Bleomycin sulfate is aDNA synthesisinhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumorantibiotic^[1].

DNA/RNA Synthesis^[1]

Bleomycin (BLM) sulfate is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation^[1].
The IC₅₀value of Bleomycin sulfate for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin (BLM); IC₅₀values are 14.2±2.8 nM and 13.0±1.1 nM, respectively^[2].
Bleomycin sulfate (50, 100 μM; for 24, 48 h) induce pulmonary fibrosis in RLE-6TN cell (50 μM) and A549 cell (100 μM)^[4].

Bleomycin sulfate treatment (3.5-4.0 mg/kg; intra-tracheal) on day 0, body weights decreases by day 4 then increases by Day 7 through the end of the study^[3].
Bleomycin sulfate (3.5-4.0 mg/kg; intra-tracheal) produces a statistically significant increase in lung hydroxyproline levels, and also increases right caudal lung lobe mass^[3].
Bleomycin sulfate (intratracheal instillation; 5.0 mg/kg/day) induces pulmonary fibrosis in eighty 8-week-old male BALB/c mice with weight about 20-30 g. Bleomycin induces the expression levels of α-SMA and collagen I^[4].
Bleomycin sulfate (intratracheally; 2.5 mg/kg; 1.25 mg/ml, approximately 50 μl per mouse) induces pulmonary fibrosis in male C57BL/6 mice (8 weeks old, average weight approximately 24.5 g)^[5].

1512.62

Solid

C₅₅H₈₅N₁₇O₂₅S₄

9041-93-4

硫酸博来霉素；硫酸博莱霉素

• Antibiotics
• Other Antibiotics

Streptomyces verticillus

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

H₂O : 255 mg/mL(168.58 mM;Need ultrasonic and warming)

DMSO : 41.67 mg/mL(27.55 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： PBS

  Solubility: 100 mg/mL (66.11 mM); Clear solution; Need ultrasonic and warming and heat to 60℃
• 2.

  请依序添加每种溶剂： Saline

  Solubility: 100 mg/mL (66.11 mM); Clear solution; Need ultrasonic
• 3.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.08 mg/mL (1.38 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (1.38 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 4.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.08 mg/mL (1.38 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (1.38 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 5.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.08 mg/mL (1.38 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (1.38 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。